Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)，was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab biosimilar is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Adalimumab biosimilar is supplied at a concentration of 50 mg/mL as a sterile, clear and colorless, preservative-free solution, which contains 1.3 mg/mL citric acid monohydrate, 1.525 mg/mL dibasic sodium phosphate dihydrate, 12 mg/mL mannitol, 0.8625 mg/mL monobasic sodium phosphate dihydrate, 1 mg/mL polysorbate 80, 6.1625 mg/mL sodium chloride, 0.3 mg/mL sodium citrate and Water for Injection.
Statement: this product is used for R&D only, not for clinical usage.
|
Name
|
Adalimumab Biosimilar
|
|
CAS NO.
|
331731-18-1
|
|
Type
|
Whole antibody
|
|
Source
|
Human
|
|
Target
|
TNF alpha
|
|
Clone
|
Monoclone
|
|
Formula
|
C6428H9912N1694O1987S46
|
|
Molecular Weight
|
148 kDa
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
中文
